LoginSign Up
Envisagenics

Envisagenics

Envisagenics is a biotechnology company founded by Maria Luisa Pineda and Martin Akerman in 2014 and headquartered in New York City, New York using artificial intelligence and RNA sequencing to develop therapeutics to treat genetic diseases.

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Funding

Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.

Timeline

People

Name
Role
Related Golden topics

Adrian Krainer

Professor & Program Chair

Maria Luisa Pineda

Co-Founder & CEO

Martin Akerman

Co-Founder & CTO

Michael Schatz

Associate Research Professor

Michael Zhang

Professor & Director

Omar Abdel-Wahab

Hematologic Oncologist

Further reading

Title
Author
Link
Type

Microsoft Announces Winners of AI Startup Competition

Meir Orbach

Web

Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant

Carolina Henriques

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References